Liver Cancer (Primary and Metastatic)

6

Review clinical trials related to Liver Cancer (Primary and Metastatic). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone. During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results. No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.

Participants needed: 2,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Mark C Burgmans, MD PhDUpdated: Jun 9, 2026Locations: 3Duration: 3 Years
Eligibility criteria

Age ≥ 18 years; [+3]

Patients who are declared incapacitated; [+1]

Status: Recruiting

Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment

This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients' full-course diagnostic and therapeutic information along with long-term outcomes. This will enable objective evaluation of prognosis and treatment efficacy in real-world clinical practice, while providing a data foundation and evidence support for subsequent optimization of clinical decision-makin

Participants needed: 800
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Tongji HospitalUpdated: Jun 4, 2026Locations: 1Duration: 2 Years
Eligibility criteria

Male or female aged ≥18 years at the time of signing the informed consent form [+2]

Status: Not yet recruiting

Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies

Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies

Participants needed: 20
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Fudan UniversityUpdated: Mar 9, 2026Locations: 1
Eligibility criteria

Age 18-80 years, regardless of gender; [+4]

Liver function classified as Child-Pugh C, unimprovable with hepatoprotective th... [+10]

Status: Recruiting

Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy

The goal of this national mutlticenter observational study is to learn and describe trends over time in the use of techniques for inducing hepatic hypertrophy in Italy. Patients will be treated according to the current clinical practice of the participating centers and will be observed from the moment of recruitment and throughout their stay. Information on vital status will be collected, as far as possible, for up to 5 years after surgery in order to record any events that occur in a timely manner. There are also plans to retrospectively collect data on patients who underwent hypertrophic techniques in the previous 10 years, in order to establish a historical cohort for each center that can be used for comparison with the prospective cohort.

Participants needed: 2,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaUpdated: Mar 3, 2026Locations: 1Duration: 5 Years
Eligibility criteria

Patients aged 18 or older [+2]

pregnant or breastfeeding woman

Status: Recruiting

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced/metastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.

Participants needed: 83
Trial details
Phase: Phase 1, Phase 2Biological sex: AllType: InterventionalSponsor: Essen BiotechUpdated: Feb 18, 2026Locations: 1
Eligibility criteria

Age ≥18 years. [+9]

Pregnant or breastfeeding. [+8]

Status: Recruiting

Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology

This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Palo Alto Veterans Institute for ResearchUpdated: Dec 26, 2025Locations: 1
Eligibility criteria

Age > or = 18 years [+2]

Not eligible for indicated procedure. [+2]